After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.; After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.; After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.; After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.), DIARRHOEA (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.), PYREXIA (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.) and FATIGUE (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Overweight. Concurrent medical conditions included Diabetes and High cholesterol. Concomitant products included METFORMIN, EMPAGLIFLOZIN (JARDIANCE) and SEMAGLUTIDE (OZEMPIC) for Diabetes.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 18-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-May-2022, the patient experienced COUGH (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.), DIARRHOEA (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.), PYREXIA (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.) and FATIGUE (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 28-Apr-2022 to 03-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COUGH (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.) and DIARRHOEA (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.) had not resolved and PYREXIA (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.) and FATIGUE (After completing full course of Paxlovid, 5 days after resumed coughing I'd had before starting, and 7 days after resumed diarrhea. Previous fever and fatigue did not resume.) had resolved.            Patient had no Allergy.